Desperate patient gets experimental stem cells for rare nerve disease

NCT ID NCT04825613

NO_LONGER_AVAILABLE Disease control Sponsor: Hope Biosciences Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provides an experimental stem cell treatment (HB-adMSCs) to an 83-year-old man with Primary Lateral Sclerosis, a rare nerve disease that causes progressive muscle weakness. The patient's own banked stem cells are used, aiming to slow the disease. This is a single-patient expanded access program, not a full clinical trial, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HB-adMSCs (adipose-derived mesenchymal stem cells)
What this could lead to: If it works, this could point toward a treatment that slows progression of Primary Lateral Sclerosis.
What could go wrong: This is a single-patient expanded access study, not a formal trial, so results may not apply to others. The treatment is still experimental with unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lateral sclerosis motor neuron disorder Papillon-Lefevre disease primary lateral sclerosis, adult, 1 Sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY LATERAL SCLEROSIS, ADULT, 1

Contacts and locations

Locations

Hope Biosciences Stem Cell Research Foundation

Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.